fundraisingBasecamp Research raises $140M for AI-designed cell therapiesLondon-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. … more ➔
fundraisingViferaXS secures up to €12M for leukemia trialGerman biotech ViferaXS has closed a Series A financing of up to €12 million, including grant funding, to advance its peptide-based cancer immunotherapy into a randomized Phase 2 trial in chronic lymphocytic … more ➔
financingScarlet gets $14M for smart red blood cellsUK biotech Scarlet Therapeutics will lead a consortium developing red blood cells that can sense physiological changes and respond to them under a U.S. Defense Advanced Research Projects Agency (DARPA) … more ➔
clinical dataRoche hits Phase 3 IgAN endpoint but holds back dataRoche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped short of disclosing the size of the effect. more ➔
drug deliveryCell therapies: breaking barriers in solid tumoursIt’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, … more ➔
licensingBoehringer backs Envisagenics in $1B RNA splicing dealBoehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments. more ➔
AIBig Picture Bio launches with £2.2M to design cancer combinationsLondon-based Big Picture Bio has launched with £2.2 million (€2.6 million) in funding to build an AI platform that designs drug combinations for cancer, starting largely with medicines that are already … more ➔
AlzheimerRemynd receives €3.5M for Alzheimer’s trialBelgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move its septin-modulating drug REM392 into patients with mild-to-moderate Alzheimer’s … more ➔
licensingNovartis licenses BoomRay radioligand asset for $900MNovartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma … more ➔
retinitis pigmentosaBeacon’s XLRP gene therapy meets pivotal U.S. endpointBeacon Therapeutics’ gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial’s separately designated European primary efficacy measure were less … more ➔
